Is Regeneron Pharmaceuticals (REGN) a risky stock?
As of July 21, 2026, Clavix grades Regeneron Pharmaceuticals (REGN) B for risk, a composite score of 68 out of 100 on an A+ to F scale, which puts REGN in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind REGN's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how REGN scores on each, as of July 21, 2026.
What's moving REGN's risk right now
Company-specific signals Clavix flags behind REGN's current grade, drawn from recent news and filings as of July 21, 2026.
The lawsuit creates legal and reputational risk for REGN and could pressure the stock as investors assess potential liability and the credibility of the company's prior communicat…
It’s the first pill that lowers blood cholesterol far better than statins, medicines that a quarter of adults take to reduce their risk of heart attack and stroke.
What a B grade means
On the Clavix A+ to F scale, REGN's composite of 68 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell REGN or any security. Grades are risk indicators, not predictions of return. Data may be delayed.